Company: ARWR
Filing Date: 2025-03-07
Form Type: 424B7
Source: 0001193125-25-049889
Chunk: 29

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-03-07
Form: 424B7
Chunk 29
---
 the designation and terms of the securities that the warrants are issued with and the number of 
 warrants issued with each security;                                                                            |

| • |     | if applicable, the date from and after which the warrants and any securities issued with the warrants will be 
 separately transferable;                                                                                      |

| • |     | the number of shares and price of common stock or preferred stock that may be purchased upon exercise of a 
 warrant;                                                                                                   |

| • |     | the dates on which the right to exercise the warrants commences and expires; |

| • |     | if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time; |

| • |     | if applicable, a discussion of material U.S. federal income tax considerations; |

| • |     | anti-dilution provisions of the warrants, if any; |

| • |     | redemption or call provisions, if any, applicable to the warrants; and |

| • |     | any additional terms of the warrants, including terms, procedures and limitations relating to the exchange and 
 exercise of the warrants.                                                                                      |

Exercise of Warrants Each warrant will entitle the holder of the warrant to purchase at the exercise price set forth in the applicable prospectus supplement the principal amount of debt securities or shares of common stock or preferred stock being offered. Holders may exercise warrants at any time up to the close of business on the expiration date set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will be void. Holders may exercise warrants as set forth in the prospectus supplement relating to the warrants being offered. Until a holder exercises the warrants to purchase any securities underlying the warrants, the holder will not have any rights as a holder of the underlying securities by virtue of ownership of warrants. 15

SELLING STOCKHOLDERS

Selling stockholders are persons or entities that, directly or indirectly, have acquired or will from time to time acquire from us, our
securities. Such selling stockholders may be parties to registration rights agreements with us, or we otherwise may have agreed or will agree to register their securities for resale. The initial purchasers of our securities, as well as their
transferees, pledgees, donees or successors, all of whom we refer to as “selling stockholders,” may from time to time offer and sell our securities pursuant to this prospectus, any applicable prospectus supplement or post-effective
amendment.

Information regarding